Business Context and Reporting Period
This Form 8-K Current Report was filed by OvaScience, Inc. (not Tempest Therapeutics, Inc.) on January 10, 2014, covering events occurring between January 6 and January 10, 2014. The filing details significant changes to the Company's Board of Directors and senior executive management team.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on corporate governance and personnel changes. The only financial data disclosed relates to specific compensation arrangements:
- Director Compensation: Marc Kozin will receive an annual board fee of $35,000 and a committee fee of $3,750.
- Stock Options (Director): Mr. Kozin will be granted options for 8,650 shares initially, with future grants of 6,500 shares annually.
- Executive Separation Package: Alison Lawton will receive nine months of base salary and the right to exercise options for 92,223 shares at an exercise price of $13.50 per share.
Material Changes
The filing reports the following material changes in personnel:
- Board Election: Marc Kozin was elected as a Class I Director to replace Jonathan Tilly, Ph.D., who resigned on January 6, 2014. Dr. Tilly's resignation was not due to any disagreement with the Company.
- Executive Appointments: David Stern was appointed Executive Vice President, Global Commercial Operations, effective February 2014. Christopher Bleck was appointed Head of Sales and Marketing.
- Executive Departure: Alison Lawton, Chief Operating Officer, is leaving the Company to pursue other opportunities.
Outlook, Risks, and Management Commentary
Management commentary indicates that the appointment of David Stern is in preparation for the international introduction of the Company's product, AUGMENT SM. The filing notes that Mr. Kozin brings nearly 30 years of experience in strategy consulting and M&A advisory. No specific financial risks, contingencies, or unusual items were disclosed in this report.
Investor Verification Checklist
- Verify the exact vesting schedule and grant date for Marc Kozin's stock options to be determined in March 2014.
- Confirm the total cash value of Alison Lawton's separation package based on her undisclosed base salary.
- Review the press release (Exhibit 99.1) for additional details on the strategic rationale for the new commercial leadership.
- Monitor the Company's progress on the international launch of AUGMENT SM following the new executive appointments.